Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY4086940 Compared With Placebo in Adult Participants With Obesity or Overweight and Without Type 2 Diabetes

NCT07890376 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07890376 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY4086940 Compared With Placebo in Adult Participants With Obesity or Overweight and Without Type 2 Diabetes
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
June 30, 2028
Enrollment
460 (estimated)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

Arms

As registered; 10 arms.

  • LY4086940 Dose 1 ExperimentalLY4086940

    Participants will receive LY4086940 orally

  • LY4086940 Dose 2 ExperimentalLY4086940

    Participants will receive LY4086940 orally

  • LY4086940 Dose 3, Titration Schedule A ExperimentalLY4086940

    Participants will receive LY4086940 orally

  • LY4086940 Dose 3, Titration Schedule B ExperimentalLY4086940

    Participants will receive LY4086940 orally

  • LY4086940 Dose 4 ExperimentalLY4086940

    Participants will receive LY4086940 orally

+5 more arms

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Percent Change from Baseline in Body Weight Baseline, Week 32

Lead sponsor's other trials

Eli Lilly and Company, most recent start first.

Similar trials

Same condition (Weight Loss) and phase, most recent start first.